• 6 August 2015

    Avitide, Inc., a biotech company dedicated to the rapid discovery and development of on-demand affinity purification solutions for the biopharmaceutical industry, today announced the closing of its Series C financing. NeoMed Management led the financing, with participation from existing investors Polaris Partners, OrbiMed Advisors, SV Life Sciences and Borealis Ventures. Claudio Nessi (NeoMed) joined Avitide’s Board of Directors. The proceeds will accelerate commercialization of Avitide’s on-demand affinity purification platform, with a focus on biopharmaceutical drug products that include an array of molecules such as proteins, enzymes, antibody-based therapeutics, recombinant vaccines, gene therapies and biosimilars. The financing is expected to take the company to profitability within the next two years.

  • 4 August 2015

    JenaValve Technology, Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical technology financial executive Peter C. Wulff as Chief Financial Officer (CFO), effective immediately. Mr. Wulff will be based in Irvine, Calif. at JenaValve’s new corporate headquarters. “

  • 30 July 2015

    Genkyotex, the leading developer of selective NOX inhibitors, announced today publication of results from two independent studies confirming the important role played by both NOX1 and NOX4 enzymes in the development of liver fibrosis. This research, conducted at University of California, San Diego, and University of California, Davis, supports the use of dual NOX1&4 inhibitors for the treatment of liver fibrosis, such as nonalcoholic steatohepatitis (NASH). Genkyotex’s lead inhibitor, GKT137831, is in a Ph2 trial in diabetic nephropathy, the data from which is also being analyzed to support the company’s plan to evaluate the drug in a range of fibrotic diseases. 

  • 22 July 2015

    Wilson Therapeutics AB, a privately-held biopharmaceutical company developing novel treatments for patients with Wilson’s Disease, today announced the appointment of Dr. Carl Bjartmar as chief medical officer (CMO). Dr. Bjartmar will report to Jonas Hansson, chief executive officer, and will join the company’s management team.

  • 9 July 2015

    InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.